Ongoing Clinical Trials Exhibit
1. CALGB-140503
A Phase III randomized trial of lobectomy versus sublobar resection for small (≤2 cm) peripheral NSCLC
2. ACOSOG-Z4099
Surgery with or without internal radiation therapy compared to stereotactic body radiation therapy in treating patients with high-risk Stage I NSCLC
3. CALGB-30610/RTOG-0538
Surgery with or without internal radiation therapy compared to stereotactic body radiation therapy in treating patients with high-risk Stage I NSCLC
4. ECOG-E1505
A Phase III study of adjuvant chemotherapy with or without bevacizumab for patients with completely resected Stage IB (>4 cm)-IIIA NSCLC
5. RADIANT
A Phase III study of erlotinib after surgery with or without adjuvant chemotherapy for NSCLC with EGFR-positive tumors
6. SELECT/07-259
A Phase II trial of adjuvant erlotinib in patients with resected early-stage NSCLC and confirmed mutations in the epidermal growth factor receptor
7. CTONG-1104
A Phase III trial of gefitinib versus vinorelbine/platinum as adjuvant treatment for Stage II-IIIA (N1-N2) NSCLC with EGFR mutation
8. EMERGING
A randomized Phase II/III trial of erlotinib versus gemcitabine/cisplatin as (neo)adjuvant treatment for NSCLC
9. CLCSG-001
A Phase II study of erlotinib versus vinorelbine/cisplatin as adjuvant treatment for Stage IIIA NSCLC with EGFR mutations
10. RTOG-1210/ALLIANCE 31101
A Phase II randomized trial of up-front therapy with erlotinib or crizotinib followed by chemoradiation therapy versus chemoradiation therapy only in Stage III NSCLC with either EGFR TK mutation or ALK fusion
11. RTOG-1106
A Phase II study of positron emission tomography and computed tomography in guiding radiation therapy (RT) in patients with Stage III NSCLC
12. SWOG-S0819
A Phase III study evaluating carboplatin/paclitaxel or carboplatin/paclitaxel/bevacizumab (bev) with or without concurrent cetuximab (cet) in advanced NSCLC
13. CALGB-30801
A Phase III trial evaluating selective COX-2 inhibition in COX-2-expressing advanced NSCLC
14. CALGB-30607
Sunitinib as maintenance therapy in treating Stage III or Stage IV NSCLC previously treated with combination chemotherapy
15. ECOG-E5508
A Phase III study of maintenance therapy with bevacizumab, pemetrexed or the combination after induction with carboplatin, paclitaxel and bevacizumab for advanced nonsquamous NSCLC
16. AvaALL
A Phase III trial of second-line bevacizumab and standard therapy in NSCLC previously treated with bevacizumab and platinum doublet-containing chemotherapy
17. NCT01168973
A Phase III randomized trial of docetaxel and ramucirumab versus docetaxel and placebo for Stage IV NSCLC with disease progression after 1 prior platinum-based therapy
18. CA209-017
A Phase III trial of the anti-PD-1 monoclonal antibody BMS-936558 versus docetaxel in previously treated advanced or metastatic squamous cell NSCLC
19. MetLung
A Phase III trial of onartuzumab (MetMAb) and erlotinib in patients with MET diagnostic-positive advanced NSCLC previously treated with standard chemotherapy
20. LUX-LUNG 8
A Phase III trial of afatinib (BIBW 2992) versus erlotinib for the treatment of advanced squamous cell lung cancer after first-line platinum-based chemotherapy